Dealmaking Quarterly Statistics, Q4 2022

A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, October-December 2022

During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.

Qstats Image 1
• Source: Alamy

Biopharma merger and acquisition value for the fourth quarter of 2022 reached $35.7bn from 41 transactions, 21 of which had disclosed values. Making up 78% of the Q4 total wasAmgen, Inc.’s proposed $27.8bn acquisition of Horizon Therapeutics plc. This deal and three other M&A transactions were the only ones to hit or exceed the billion-dollar mark during Q4 (see Exhibit 1), but nine other deals during this period were valued at $100m or more.

The Amgen/Horizon deal – which marked the largest M&A of the quarter and also for the biopharma industry overall in...

More from Deal-Making

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.